A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to PaclitaxelJinhua Zhou, Robert C. Bast, Yan Wang et al.|Clinical Cancer Research|2016Cited by 77
Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemmaHeba Alshaker, Dmitri Pchejetski, Keith Sacco et al.|Oncotarget|2015Cited by 76
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancerDmitri Pchejetski, Leonardo Monzon, Albandri Alfraidi et al.|Journal of Cancer Research and Clinical Oncology|2015Cited by 28
Supplementary data from A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to PaclitaxelJinhua Zhou, Robert C. Bast, Shu Zhang et al.|Unknown|2023Cited by 0
Supplementary table from A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to PaclitaxelJinhua Zhou, Robert C. Bast, Albandri Alfraidi et al.|Unknown|2023Cited by 0